| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.91.3.691 |
| P698 | PubMed publication ID | 7828295 |
| P50 | author | Ian Crozier | Q109367584 |
| Hamid Ikram | Q109394157 | ||
| P2093 | author name string | Young J | |
| Frey M | |||
| Dickstein K | |||
| Cleland J | |||
| Klinger G | |||
| Awan N | |||
| Makris L | |||
| Stephen N | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart failure | Q181754 |
| losartan | Q410074 | ||
| hemodynamics | Q1642137 | ||
| P304 | page(s) | 691-697 | |
| P577 | publication date | 1995-02-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group. | |
| P478 | volume | 91 |
| Q39461053 | A cardiologist's perspective on evolving concepts in the management of congestive heart failure |
| Q36109110 | A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure |
| Q35106471 | ACE inhibitors and ARBs in chronic heart failure: the established, the expected, and the pragmatic |
| Q73128324 | ARCTIC: assessment of haemodynamic response in patients with congestive heart failure to telmisartan: a multicentre dose-ranging study in Canada |
| Q35837657 | AT(1)-receptor blockade and sympathetic neurotransmission in cardiovascular disease |
| Q77925494 | AT1 angiotensin II receptor inhibition in pacing-induced heart failure: effects on left ventricular performance and regional blood flow patterns |
| Q77925498 | Angiotensin AT1 receptor inhibition, angiotensin-converting enzyme inhibition, and combination therapy with developing heart failure: cellular mechanisms of action |
| Q33718262 | Angiotensin II and connective tissue: homeostasis and reciprocal regulation |
| Q34286755 | Angiotensin II receptor (AT1) antagonists in heart failure after Val-HeFT--Quo Vadis? |
| Q33851581 | Angiotensin II receptor antagonists |
| Q34716915 | Angiotensin II receptor antagonists in chronic heart failure: where do they fit? |
| Q40892935 | Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease |
| Q41102136 | Angiotensin II receptor antagonists: the prototype losartan |
| Q73547027 | Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure |
| Q41259348 | Angiotensin II type 1 receptor induced signal-transduction pathways as new targets for pharmacological treatment of the renin-angiotensin system |
| Q41701250 | Angiotensin II type-I receptor antagonists in the treatment of heart failure |
| Q41169263 | Angiotensin receptor antagonists--a new class of antihypertensive drug |
| Q40369188 | Angiotensin receptor antagonists: focus on losartan |
| Q34283096 | Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure |
| Q24199125 | Angiotensin receptor blockers for heart failure |
| Q24792591 | Angiotensin receptor blockers in heart failure after the ELITE II trial |
| Q77583415 | Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials |
| Q34209423 | Angiotensin receptor blockers: evidence for preserving target organs. |
| Q35626136 | Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: what we know and current controversies |
| Q41495127 | Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists and calcium channel blocking agents: a review of potential benefits and possible adverse reactions |
| Q44930355 | Beneficial effect of candesartan treatment on cardiac autonomic nervous activity in patients with chronic heart failure: simultaneous recording of ambulatory electrocardiogram and posture |
| Q43703355 | Can Sartane help a failing heart? AT1-receptor antagonists in cardiac insufficiency |
| Q33403831 | Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis |
| Q47913024 | Clinical pharmacokinetics of vasodilators. Part I. |
| Q73746095 | Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators |
| Q33703340 | Comparative safety and tolerability of angiotensin II receptor antagonists |
| Q95341476 | Comparison of losartan and captopril in ELITE II |
| Q74598270 | Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan |
| Q71870087 | Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure |
| Q41107143 | Current drug treatment and treatment patterns with antihypertensive drugs |
| Q42593004 | Current issues in cardiac care. |
| Q34032471 | Diastolic dysfunction in the elderly. Genesis and diagnostic and therapeutic implications |
| Q77129290 | Dilated Cardiomyopathy |
| Q41682222 | Do ACE inhibitors provide protection for the heart in the clinical setting of acute myocardial infarction? |
| Q35372556 | Does the addition of losartan improve the beneficial effects of ACE inhibitors in patients with anterior myocardial infarction? A pilot study |
| Q77291893 | Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure |
| Q35097098 | Drugs that interrupt the renin-angiotensin system should be among the preferred initial drugs to treat hypertension |
| Q31383623 | Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. |
| Q77906160 | Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis |
| Q73504162 | Effects of angiotensin II receptor blockade on N-terminal proatrial natriuretic factor plasma levels in chronic heart failure |
| Q34150300 | Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan |
| Q35027144 | Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and beta-adrenergic neuroeffector mechanisms in transgenic (mREN2)27 rats. |
| Q73029172 | Effects of the angiotensin II antagonist losartan on endothelin-1 and norepinephrine plasma levels during cold pressor test in patients with chronic heart failure |
| Q31966048 | Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) i |
| Q49083618 | Efficacy of losartan as add-on therapy to prevent aortic growth and ventricular dysfunction in patients with Marfan syndrome: a randomized, double-blind clinical trial |
| Q37818472 | Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists |
| Q28564609 | Endogenous or overexpressed cGMP-dependent protein kinases inhibit cAMP-dependent renin release from rat isolated perfused kidney, microdissected glomeruli, and isolated juxtaglomerular cells |
| Q46976515 | Evaluation of enalapril+losartan treatment with cardiopulmonary exercise test in patients with left ventricular dysfunction |
| Q44339339 | First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteers |
| Q34237411 | Formulating clinical strategies for angiotensin antagonism: a review of preclinical and clinical studies |
| Q36577692 | Future pharmacologic agents for treatment of heart failure in children |
| Q74152297 | Haemodynamic, neurohumoral and exercise effects of losartan vs. captopril in chronic heart failure: results of an ELITE trial substudy. Evaluation of Losartan in the Elderly |
| Q43086634 | Haemodynamic, renal sodium handling, and neurohormonal effects of acute administration of low dose losartan, an angiotensin II receptor antagonist, in preascitic cirrhosis |
| Q33986289 | Heart failure with normal systolic function |
| Q44702101 | Impaired neuronal and vascular responses to angiotensin II in a rabbit congestive heart failure model |
| Q45737692 | Inhibition of brain angiotensin III attenuates sympathetic hyperactivity and cardiac dysfunction in rats post-myocardial infarction |
| Q36835377 | Inhibitors of the renin-angiotensin system in established cardiac failure |
| Q42941858 | Losartan reduces mortality in a genetic model of heart failure. |
| Q82092603 | Losartan was associated with a similar rate of renal dysfunction and worsening heart failure as captopril with fewer adverse effects |
| Q33914247 | Losartan: a review of its use, with special focus on elderly patients |
| Q34070051 | Management of heart failure: evidence versus practice. Does current prescribing provide optimal treatment for heart failure patients? |
| Q34239882 | Medical management of mild-to-moderate heart failure before the advent of beta blockers |
| Q77802846 | Medical therapy of chronic heart failure. Role of ACE inhibitors and beta-blockers |
| Q30608935 | Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. Losartan Heart Failure Mortality Meta-analysis Study Group |
| Q43573554 | Modulation of oxidative stress by a selective inhibition of angiotensin II type 1 receptors in MI rats |
| Q41084357 | Molecular biology of angiotensin receptors and their role in human cardiovascular disease |
| Q31989723 | New competition in the realm of renin-angiotensin axis inhibition; the angiotensin II receptor antagonists in congestive heart failure |
| Q41177950 | Novel drugs and current therapeutic approaches in the treatment of heart failure |
| Q33885912 | Optimising management of patients with advanced heart failure: the importance of preventing progression |
| Q77709200 | Overview of angiotensin II-receptor antagonists |
| Q41333137 | Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. |
| Q24811026 | Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease |
| Q57487974 | Population Pharmacokinetic-Pharmacodynamic Modelling of Angiotensin Receptor Blockade in Healthy Volunteers |
| Q33650699 | Practical considerations of the pharmacology of angiotensin receptor blockers |
| Q73164612 | Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) |
| Q45063510 | Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure |
| Q35368799 | Regulation of peripheral vascular tone in patients with heart failure: contribution of angiotensin II |
| Q35097846 | Renin-angiotensin-aldosterone system: fundamental aspects and clinical implications in renal and cardiovascular disorders |
| Q40748761 | Spectrum of use for the angiotensin-receptor blocking drugs |
| Q77296413 | Successes and failures of current treatment of heart failure |
| Q93046946 | Testing the Translational Power of the Zebrafish: An Interspecies Analysis of Responses to Cardiovascular Drugs |
| Q40880465 | The AHCPR clinical practice guideline for heart failure revisited |
| Q41653536 | The clinical significance of neurohormonal activation |
| Q40991772 | The renin-angiotensin system in left ventricular remodeling |
| Q35056228 | The role of angiotensin II receptor blockers in the treatment of heart failure patients |
| Q34510983 | Treatment of heart failure in patients with diabetes mellitus |
| Q38410791 | Under-Utilization of Implantable Cardioverter Defibrillators in Patients with Heart Failure - The Current State of Sudden Cardiac Death Prophylaxis |
| Q61716880 | Update of ELITE-II, BEST, CHAMP, and IMPRESS clinical trials in heart failure |
| Q77309728 | Valsartan in heart failure patients previously untreated with an ACE inhibitor |
| Q28069387 | Varying effects of recommended treatments for heart failure with reduced ejection fraction: meta-analysis of randomized controlled trials in the ESC and ACCF/AHA guidelines |
| Q73292088 | Vasodilators in the treatment of pediatric heart failure |
| Q48568169 | Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects |
| Q74245995 | [Therapy of chronic cardiac insufficiency with ACE inhibitors versus AT1 receptor antagonists. Is there a difference?] |
Search more.